The estimated Net Worth of Wendy L Dixon is at least $3.88 Миллион dollars as of 14 June 2022. Wendy Dixon owns over 7,585 units of Incyte stock worth over $3,353,718 and over the last 16 years he sold INCY stock worth over $0. In addition, he makes $526,302 as Independent Director at Incyte.
Wendy has made over 11 trades of the Incyte stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 7,585 units of INCY stock worth $478,841 on 14 June 2022.
The largest trade he's ever made was exercising 53,334 units of Incyte stock on 6 November 2019 worth over $664,542. On average, Wendy trades about 1,813 units every 34 days since 2008. As of 14 June 2022 he still owns at least 53,124 units of Incyte stock.
You can see the complete history of Wendy Dixon stock trades at the bottom of the page.
Dr. Wendy L. Dixon, Ph.D., is an Independent Director of Incyte Corporation. Dr. Dixon served as Chief Marketing Officer and President, Global Marketing for Bristol Myers Squibb Company from December 2001 until May 2009 and served on the Chief Executive Officer's Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing—USHH at Merck & Co., Inc., and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, Inc. and Centocor, Inc. and various positions at SmithKline & French Pharmaceuticals in marketing, regulatory affairs, project management and as a biochemist.
As the Independent Director of Incyte, the total compensation of Wendy Dixon at Incyte is $526,302. There are 15 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Wendy Dixon is 64, he's been the Independent Director of Incyte since 2010. There are 4 older and 22 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Wendy's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... и Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: